Hot Investor Mandate 1: Mid Atlantic VC Looks Worldwide for Cutting Edge Clinical Stage Therapeutics

19 Oct

A venture capital firm based in New Jersey makes initial investments from $5-$10M with $25M over the lifetime of the company. The firm invests globally, and has particular experience with partners in US, Israel, and England.

The firm seeks early-stage nanotechnology and stem cell research, particularly in cancer, rehabilitation, and regenerative medicine. The firm is only interested in clinical stage Ph I/II technology. The firm focuses their expertise in regenerative medicine, stem cell biology, immunology, oncology, and nanotechnology to identify opportunities in the treatment of a broad range of diseases. Specific to oncology, the firm is interested in novel cancer therapies, immunotherapy, new chemotherapies, targeted therapy, management of adverse consequences, and quality of life improvement.

The firm requires management teams with experience in the field. The firm seeks board representation post-investment, and remains actively supportive with portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: